Random migration contributes to cytotoxicity of activated CD8+ T-lymphocytes but not NK cells

Anticancer Research

Volumn 34, Issue 8, 2014, Pages 3947-3956

  Onishi, Hideya ^a   Kiyota, Akifumi ^b   Koya, Norihiro ^b   Tanaka, Hiroto ^b   Umebayashi, Masayo ^b   Katano, Mitsuo ^b   Morisaki, Takashi ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b Fukuoka General Cancer Clinic   (Japan)

Author keywords

CD8+ T cell; Cytotoxicity; Immunotherapy; NK cell; Random migration

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; FINGOLIMOD; NATURAL KILLER CELL RECEPTOR NKG2D; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE MIGRATION; MIGRATION INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; RANDOM MIGRATION; T LYMPHOCYTE ACTIVATION; TIME LAPSE IMAGING; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CYTOTOXICITY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION;

CD8+ T CELL; CYTOTOXICITY; IMMUNOTHERAPY; NK CELL; RANDOM MIGRATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C;

EID: 84908698925     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature 480: 480-489, 2011.
2. Dougan M and Dranoff G: Immune therapy for cancer. Ann Rev Immunol 27: 83-117, 2009.
3. Onishi H, Morisaki T, Baba E, Nakamura M, Inaba S, Kuroki H, Matsumoto K and Katano M: Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma. Anticancer Res 31: 3995-4005, 2011.
4. Mandala S, Hajdu R, Bergstrom J, Quackenbush E Xie J: Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W and Rosen H Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349, 2002.
5. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M and Lynch KR: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 16: 1874-1878, 2002.
6. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL and Cyster JG: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427 : 355-360, 2004.
7. Thangada S, Khanna KM, Blaho VA, Oo ML, Im DS, Guo C, Lefrancois L and Hla T: Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med 207: 1475-1483, 2010.
8. Arnon TI, Xu Y, Lo C, Pham T, An J, Coughlin S, Dorn GW and Cyster JG: GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science 333: 1898-1903, 2011.
9. Kluk MJ, Ryan KP, Wang B, Zhang G, Rodig SJ and Sanchez T: Sphingosine-1-phosphate receptor 1 in classical Hodgkin lymphoma: assessment of expression and role in cell migration. Lab Invest 93: 462-471, 2013.
10. Edsall LC and Spiegel S: Enzymatic measurement of sphingosine 1-phosphate, Anal Biochem 272 : 80-86, 1999.
11. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y and Cyster JG: Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309 : 1735-1739, 2005.
12. Takabe K, Paugh SW, Milstien S and Spiegel S: "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60: 181-195, 2008.
13. Franciszkiewicz K, Boissonnas A, Boutet M, Combadière C and Mami-Chouaib F: Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 72: 6325-6332, 2012.
14. Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP and Saddoughi SA: Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood 117: 5941-5952, 2011.
15. Kim ES, Kim JS, Kim SG, Hwang S, Lee CHand Moon A: Sphingosine 1-phosphate regulates matrix metalloproteinase-9 expression and breast cell invasion through S1P3-Ginnodataalphaq coupling. J Cell Sci 124: 2220-2230, 2011.
16. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E, Theuer A, Hla T and Wood J: Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66: 221-231, 2006.
17. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR Lin CY and Hla T: Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282: 9082-9089, 2007.
18. + T-lymphocytes) in the control of human tumors. Cancer Immunol Immunother 58: 801-808, 2009.
19. Morisaki T, Onishi H and Katano M: Cancer Immunotherapy using NKG2D and DNAM-1 systems. Anticancer Res 32: 2241-2248, 2012.
20. Onishi H, Morisaki T, Kiyota A, Koya N, Tanaka H, Umebayashi M and Katano M: The Hedgehog inhibitor cyclopamine impairs the benefits of immunotherapy with activated T- and NK-lymphocytes derived from patients with advanced cancer. Cancer Immunol Immunother 62 : 1029-1039, 2013.
21. + regulatory T-cells are predictive markers for recurrence and survival in patients with colorectal cancer. Clin Immunol 146: 26-33, 2013.
22. Milstien S and Spiegel S: Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. Cancer Cell 9: 148-150, 2006.
23. Payne AS and Cornelius LA: The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 118: 915-922, 2002.
24. Gao D, Vahdat LT, Wong S, Chang JC and Mittal V: Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res 72 : 4883-4889, 2012.